Syndax Pharmaceuticals, Inc. (SNDX - Free Report) was a big mover last session, as the company saw its shares rise over 14% on the day. The upside was driven after the company announced entering into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The news also led to far more shares changing hands than in a normal session, resulting in solid volume. This reverses the recent trend of the company, as the stock is now down 14.8% since Dec 7.
None of the estimates for this stock were revised over the last 30 days, while the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Syndax Pharmaceuticals carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the same industry is Arbutus Biopharma Corporation (ABUS - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is SNDX going up? Or down? Predict to see what others think: Up or Down
The Best Place to Start Your Stock Search
Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Syndax Pharmaceuticals, Inc. (SNDX - Free Report) was a big mover last session, as the company saw its shares rise over 14% on the day. The upside was driven after the company announced entering into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The news also led to far more shares changing hands than in a normal session, resulting in solid volume. This reverses the recent trend of the company, as the stock is now down 14.8% since Dec 7.
None of the estimates for this stock were revised over the last 30 days, while the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Syndax Pharmaceuticals carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the same industry is Arbutus Biopharma Corporation (ABUS - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is SNDX going up? Or down? Predict to see what others think: Up or Down
The Best Place to Start Your Stock Search
Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on SNDX - FREE
Get the latest research report on ABUS - FREE